High-grade gliomas are very challenging to treat successfully. In this study, researchers are evaluating radiation therapy plus vorinostat, bevacizumab, or temozolomide followed by maintenance chemotherapy in children newly diagnosed with high-grade gliomas.
Vorinostat is approved for a rare cancer called cutaneous T-cell lymphoma, but its use in children and in patients with glioma is considered investigational. It is a drug called a histone deacetylase (HDAC) inhibitor. It prevents cancer cells from reproducing by interfering with certain signaling pathways. Bevacizumab and temozolomide are both already used to treat glioma in adults.
In this Children’s Oncology Group study, patients will be randomly assigned to treatment with radiation therapy and either vorinostat, bevacizumab, or temozolomide. All patients will then receive maintenance therapy with bevacizumab and temozolomide to try to reduce the risk of recurrence.